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ABSTRACT Macrolide antibiotics are cornerstones in the treatment of Mycobacterium
massiliense lung disease. Despite the emergence of resistance, limited data on
macrolide-resistant M. massiliense lung disease are available. This study evaluated
the clinical features and treatment outcomes of patients and the molecular charac-
teristics of macrolide-resistant M. massiliense isolates. We performed a retrospective
review of medical records and genetic analyses of clinical isolates from 15 patients
who had macrolide-resistant M. massiliense lung disease between September 2005
and February 2015. Nine patients (60%) had the nodular bronchiectatic form of the
disease, and six (40%) had the ﬁbrocavitary form. Before the detection of macrolide
resistance, three patients (20%) were treated with macrolide monotherapy, four
(27%) with therapy for presumed Mycobacterium avium complex infections, and
eight (53%) with combination antibiotic therapy for M. massiliense lung disease. The
median treatment duration after the detection of resistance was 18.7 months (inter-
quartile range, 11.2 to 39.8 months). Treatment outcomes were poor, with a favor-
able outcome being achieved for only one patient (7%), who underwent surgery in
addition to antibiotic therapy. The 1-, 3-, and 5-year mortality rates were 7, 13, and
33%, respectively. Of the 15 clinical isolates, 14 (93%) had point mutations at posi-
tion 2058 (n  9) or 2059 (n  5) of the 23S rRNA gene, resulting in macrolide resis-
tance. Our study indicates that treatment outcomes are poor and mortality rates are
high after the development of macrolide resistance in patients with M. massiliense
lung disease. Thus, preventing the development of macrolide resistance should be a
key consideration during treatment.
KEYWORDS nontuberculous mycobacteria, Mycobacterium massiliense, macrolides,
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Pulmonary disease caused by nontuberculous mycobacteria (NTM) is increasingworldwide (1, 2); for patients with chronic lung diseases, such as bronchiectasis or
cystic ﬁbrosis, the Mycobacterium abscessus complex (MABC) is the most important
cause of pulmonary infections due to rapidly growing mycobacteria (3, 4). Currently,
the MABC can be divided into three subspecies, i.e., M. abscessus subsp. abscessus
(hereafter M. abscessus), M. abscessus subsp. massiliense (hereafter M. massiliense), and
M. abscessus subsp. bolletii (hereafter M. bolletii) (5, 6). Of the three subspecies, M.
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abscessus is the most common pathogen (45 to 65%), followed by M. massiliense (20 to
55%) and M. bolletii (1 to 18%) (7).
The response rates for macrolide-based antibiotic therapy are much higher among
patients with M. massiliense lung disease than among those with M. abscessus lung
disease (8–10). This is likely due to the presence of a functional ribosomal methyl
transferase erm(41) gene in M. abscessus, which results in inducible macrolide resis-
tance, observed as susceptibility to macrolides at day 3 but resistance at day 14 of drug
susceptibility testing (DST). In contrast, the erm(41) gene is nonfunctional in M. massil-
iense, and inducible resistance does not occur (11–14). Therefore, macrolide antibiotics,
such as clarithromycin and azithromycin, are cornerstones in the antibiotic treatment of
M. massiliense lung disease (15–18).
Acquired macrolide resistance (observed as resistance at day 3 of DST) can develop
during macrolide antibiotic treatment of M. massiliense lung disease, however, and is
conferred by mutations in the drug-binding pocket of the 23S rRNA gene (rrl), at
nucleotide positions 2058 and 2059 (19–22). Although previous laboratory studies
observed this acquired macrolide resistance in some M. massiliense clinical isolates, no
published data are available regarding the risk factors or clinical characteristics of
macrolide-resistant M. massiliense lung disease or the treatment outcomes of affected
patients. Our aims in this study were to evaluate the clinical features and treatment
outcomes of patients with macrolide-resistant M. massiliense lung disease, as well as to
examine the molecular characteristics of the pathogen.
RESULTS
Patient characteristics. A total of 15 patients were diagnosed with macrolide-
resistant M. massiliense lung disease during the study period. The clinical characteristics
of the patients are summarized in Table 1. Some of the clinical data for two of the
patients were included in a recently published article (18); data for the remaining
patients have not been reported previously. There were 10 female patients (67%), and
the median age of all patients was 57 years (interquartile range [IQR], 48 to 67 years).
TABLE 1 Clinical characteristics at the time of diagnosis of macrolide-resistant Mycobacterium massiliense lung disease
Characteristica Total
Nodular bronchiectatic
form Fibrocavitary form P
No. (%) of patients 15 (100) 9 (60) 6 (40)
Female (no. [%]) 10 (67) 7 (78) 3 (50) 0.329
Age (median [IQR]) (yr) 57 (48–67) 57 (46–65) 61 (51–72) 0.388
BMI (median [IQR]) (kg/m2) 21.1 (18.6–22.3) 21.5 (19.9–23.1) 18.4 (16.5–22.0) 0.088
Nonsmoker (no. [%]) 11 (73) 8 (89) 3 (50) 0.235
Previous treatment for pulmonary TB (no. [%]) 9 (60) 3 (33) 6 (100) 0.028
Previous treatment for NTM lung disease (no. [%]) 1 (7) 0 1 (17) 0.4
Comorbidities (no. [%])
COPD 5 (33) 2 (22) 3 (50) 0.329
Bronchiectasis 11 (73) 9 (100) 2 (33) 0.011
Chronic pulmonary aspergillosis 2 (13) 0 2 (33) 0.143
Chronic heart disease 1 (7) 1 (11) 0 1.0
Laboratory ﬁndings
Positive sputum AFB smear (no. [%]) 13 (87) 7 (78) 6 (100) 0.486
ESR (median [IQR]) (mm/h) 56 (45–75) 48 (19–66) 78 (56–86) 0.018
CRP level (median [IQR]) (mg/dl) 1.03 (0.25–4.85) 0.56 (0.10–1.50) 5.65 (2.09–9.33) 0.026
Cavitary lesions on HRCT scans (no. [%]) 10 (67) 4 (44) 6 (100) 0.044
Pulmonary function test results
FVC (median [IQR]) (liters) 2.81 (2.08–3.44) 2.81 (2.53–3.46) 2.43 (1.72–3.49) 0.529
FVC (median [IQR]) (% of predicted) 81 (67–93) 84.0 (80.5–97.5) 68.0 (47.0–96.5) 0.224
FEV1 (median [IQR]) (liters) 1.97 (1.40–2.55) 1.97 (1.65–2.65) 1.74 (0.87–2.44) 0.456
FEV1 (median [IQR]) (% of predicted) 75 (49–88) 81.0 (71.0–91.5) 61.5 (39.5–87.3) 0.224
aBMI, body mass index; TB, tuberculosis; NTM, nontuberculous mycobacteria; COPD, chronic obstructive pulmonary disease; AFB, acid-fast bacilli; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; HRCT, high-resolution computed tomography; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s.
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Nine patients (60%) had a history of previous treatment for pulmonary tuberculosis.
One patient (7%) had a history of previous treatment for NTM lung disease caused by
a mixed infection with M. intracellulare and M. massiliense.
Sputum smears were positive for acid-fast bacilli (AFB) for 13 patients (87%) at the
time macrolide resistance was detected. Chest radiography and high-resolution com-
puted tomography (HRCT) ﬁndings were available for all patients. Nine patients (60%)
had the nodular bronchiectatic form of the disease, and six (40%) had the ﬁbrocavitary
form. Cavitary lesions were found on HRCT scans for all patients with the ﬁbrocavitary
form and for four patients (44%) with the nodular bronchiectatic form. The patients
with the ﬁbrocavitary form had a higher rate of previous tuberculosis history (100%
versus 33%; P  0.028) and higher values for serum inﬂammatory markers, such as the
erythrocyte sedimentation rate (78 versus 48 mm/h; P  0.018) and C-reactive protein
levels (5.65 versus 0.56 mg/dl; P  0.026).
Antibiotic therapy before the detection of macrolide-resistant M. massiliense.
For nine patients (60%), macrolide resistance was detected when they were trans-
ferred to our hospital after long-term antibiotic treatment at other hospitals; for six
patients (40%), macrolide resistance developed during antibiotic treatment at our
institution. All patients received macrolide treatment, and the median duration of
macrolide exposure before the detection of macrolide resistance was 10.0 months
(IQR, 4.0 to 17.0 months).
Macrolide monotherapy had been prescribed for three patients (20%), i.e., one who
refused hospitalization for combination intravenous antibiotic therapy for M. massil-
iense lung disease, one for treatment of multidrug-resistant tuberculosis, and one for an
MABC infection without subspecies differentiation. Combined anti-NTM antibiotic ther-
apy, consisting of a macrolide, rifampin, and ethambutol, had been prescribed for four
patients (27%) for presumed M. avium complex (MAC) infections without precise
identiﬁcation of the etiological organism for the NTM lung disease. Combined antibiotic
therapy for M. massiliense lung disease, consisting of a macrolide, amikacin, and
cefoxitin (or imipenem), had been prescribed for eight patients (53%), two of whom
also received rifampin and ethambutol because they had mixed infections with M.
massiliense and MAC. The median duration of intravenous antibiotic exposure for these
eight patients was 2.0 weeks (IQR, 2.0 to 3.5 weeks) (Table 2).
Treatment and outcomes after the detection of macrolide-resistant M. massil-
iense. The treatment regimens after the detection of macrolide resistance and the
subsequent treatment outcomes are summarized in Table 3. After the detection of
macrolide resistance, macrolides continued to be prescribed for all patients. Amikacin
(n  10 [67%]), cefoxitin or imipenem (n  10 [67%]), ﬂuoroquinolone (n  5 [33%]),
doxycycline (n  3 [20%]), linezolid (n  1 [7%]), trimethoprim-sulfamethoxazole (n 
TABLE 2 Treatment regimens before the detection of macrolide-resistant Mycobacterium massiliense lung disease
Treatment regimena No. (%)






Macrolide monotherapy 3 (20) 3.0 (NA) 3.0 (NA) 0
Combined antibiotic therapy for presumed MAC lung disease 4 (27) 11.0 (5.4–20.3) 11.0 (5.4–20.3) 0
Macrolide  RIF  EMB 3
Macrolide  RIF  EMB  FQ 1
Combined antibiotic therapy for M. massiliense lung disease 8 (53) 12.5 (10.0–18.5) 12.0 (9.6–18.0) 2.0 (2.0–3.5)
Macrolide  IV antibiotics 2
Macrolide  IV antibiotics  RIF  EMB  FQb 2
Macrolide  IV antibiotics  FQ  DOX 4
Total 15 (100) 10.0 (4.0–17.0) 10.0 (4.0–16.5) 1.4 (0–2.0)
aIntravenous antibiotics included amikacin and cefoxitin (or imipenem). MAC, M. avium complex; IV, intravenous; RIF, rifampin; EMB, ethambutol; FQ, ﬂuoroquinolone;
DOX, doxycycline; NA, not available.
bTwo patients had mixed infections with M. massiliense and M. avium complex.
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2 [13%]), clofazimine (n  7 [47%]), and amikacin inhalation (n  5 [33%]) were used
at the discretion of the attending physicians. The median duration of antibiotic therapy
after the detection of macrolide resistance was 18.7 months (IQR, 11.2 to 39.8 months).
Ten patients (67%) received amikacin and cefoxitin (or imipenem), and the median
duration of intravenous antibiotic treatment was 3.5 weeks (IQR, 1.9 to 13.1 weeks).
Three patients (20%) underwent surgical resection; two with the ﬁbrocavitary form
underwent lobectomy at 6.4 or 1.0 months after the detection of macrolide resistance,
and one with the nodular bronchiectatic form underwent segmentectomy 8.4 months
after the detection of macrolide resistance.
Based on the occurrence and timing of sputum culture conversion (see Materials
and Methods), only one patient (7%) achieved a favorable outcome. That patient,
who showed negative sputum culture results within 12 months of treatment after
the detection of macrolide resistance, had undergone lobectomy, with the negative
sputum cultures occurring 2 months after surgery. Although surgical resection was
performed for three patients, the other two patients failed to achieve sputum
culture conversion even after surgery. One patient who had not undergone surgery
eventually achieved sputum culture conversion 25 months after the detection of
macrolide resistance. During the median follow-up period of 38.7 months (IQR, 11.4
to 41.9 months) after the detection of macrolide resistance, the all-cause mortality
rate was 33% (5/15 patients). The overall cumulative mortality rates at 1, 3, and 5
years were 7% (n  1), 13% (n  2), and 33% (n  5), respectively.
Genetic analysis of macrolide-resistant M. massiliense isolates. Macrolide-
resistant M. massiliense isolates were available from all patients for genetic analysis. We
found point mutations at position 2058 (n  9) or 2059 (n  5) of the 23S rRNA gene
in all but one of the isolates. The most common mutation was a nucleotide change
from adenine to guanine (9/15 patients [60%]), followed by cytosine (3/15 patients
[20%]) and thymine (2/15 patients [13%]) (Table 4).
DISCUSSION
In this study, we investigated the clinical characteristics and treatment outcomes of
15 patients with macrolide-resistant M. massiliense lung disease, as well as the molec-
TABLE 3 Treatment modalities and outcomes after the detection of macrolide-resistant Mycobacterium massiliense lung disease
Parametera Total (n  15)
Nodular bronchiectatic
form (n  9)
Fibrocavitary
form (n  6)
Antibiotic therapy (no. [%])
Amikacin 10 (67) 7 (78) 3 (50)
Cefoxitin or imipenem 10 (67) 7 (78) 3 (50)
Macrolide 15 (100) 9 (100) 6 (100)
Fluoroquinolone 5 (33) 4 (44) 1 (17)
Doxycycline 3 (20) 2 (22) 1 (17)
Linezolid 1 (7) 0 1 (17)
Trimethoprim-sulfamethoxazole 2 (13) 1 (11) 1 (17)
Clofazimine 7 (47) 5 (56) 2 (33)
Amikacin inhalation 5 (33) 4 (44) 1 (17)
Surgical resection (no. [%]) 3 (20) 1 (11) 2 (33)
Total treatment duration (median [IQR]) (mo) 18.7 (11.2–39.8) 19.6 (15.0–62.7) 14.7 (7.7–30.4)
Treatment outcome (no. [%])
Sputum culture conversion within 12 mo 1 (7) 0 1 (17)
Sputum culture conversion at end of treatment 2 (13) 1 (11) 1 (17)
Deaths
Time from detection of resistance to death (median [IQR]) (mo) 38.7 (11.4–41.9) 41.9 19.3
1-yr deaths (no. [%]) 1 (7) 0 1 (17)
3-yr deaths (no. [%]) 2 (13) 0 2 (33)
5-yr deaths (no. [%]) 5 (33) 2 (22) 3 (50)
Death due to NTM lung disease (no. [%]) 4 (27) 1 (11) 3 (50)
Death due to all causes (no. [%]) 5 (33) 2 (22) 3 (50)
aNTM, nontuberculous mycobacteria.
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ular characteristics of the disease isolates. Overall, the treatment outcomes were very
poor, with limited effective treatment options. Among the 15 patients, a median of 18.7
months of antibiotic treatment after the detection of macrolide resistance generated a
favorable outcome for only one patient (7%), and the 5-year mortality rate after the
development of macrolide resistance was high (33%).
Among MABC lung disease variants, M. massiliense lung disease has demonstrated
higher treatment success rates (88 to 96%) than has M. abscessus lung disease (25 to
42%) (8, 9) because inducible resistance is not found in M. massiliense, which has a
partially deleted, nonfunctional erm(41) gene (19). However, the treatment success rate
was only 7% in this study of macrolide-resistant M. massiliense lung disease. In addition
to our study results, a previous report suggested that susceptibility to clarithromycin
was the only signiﬁcant independent predictor of a favorable microbiological response
in MABC lung disease, including M. massiliense lung disease (23, 24).
Despite the clinical implications of such a report, little research on the risk
factors that contribute to the development of macrolide resistance in M. massiliense
lung disease has been published. We found macrolide monotherapy to be an
important such risk factor. Overall, seven patients (7/15 patients [47%]) had re-
ceived a macrolide without other effective antibiotics for M. massiliense before the
emergence of macrolide resistance. In particular, before transferring to our hospital,
four patients (4/15 patients [27%]) received treatment at other hospitals for pre-
sumed MAC infections, based on multiple positive NTM cultures, but without
precise identiﬁcation of the etiological organism for the NTM lung disease. Rifampin
and ethambutol, which are routinely used to treat MAC, show poor activity in both
M. abscessus and M. massiliense infections (25). Hence, the patients receiving
presumed anti-MAC treatment could be regarded as receiving macrolide mono-
therapy for M. massiliense lung disease.
We found eight patients (8/15 patients [53%]) who developed macrolide resistance
after receiving a macrolide with other antibiotics effective against M. massiliense. That
ﬁnding suggests that macrolide resistance could develop during the weak antibiotic
regimens used during the continuation phase, after completion of an initiation phase
that includes multiple intravenous antibiotics. In our previous study, we found that
macrolide resistance developed infrequently among patients with M. massiliense lung
disease (5% [2/43 patients]), even those receiving macrolide monotherapy, if the
monotherapy followed 2 weeks of combination antibiotic therapy (18). Therefore, in
our present study, the higher rate of macrolide resistance might be speciﬁcally asso-
ciated with greater bacterial burdens in those eight patients. All eight patients had
positive AFB smears, and ﬁve patients had cavitary disease at the time macrolide-
resistant M. massiliense lung disease was diagnosed. Three patients had noncavitary
nodular bronchiectatic M. massiliense lung disease, however, which suggests that the
weak antibiotic regimens used during the continuation phase could contribute to the
TABLE 4 Analysis of mutations in the 23S rRNA (rrl) gene of macrolide-resistant
Mycobacterium massiliense clinical isolates (n  15)
Point mutation at position 2058 or
2059a No. (%)
Presence of mutation 14 (93)
Adenine ¡ guanine 9 (60)
A2058G 4
A2059G 5
Adenine ¡ cytosine 3 (20)
A2058C 3
A2059C 0
Adenine ¡ thymine 2 (13)
A2058T 2
A2059T 0
Absence of mutation 1 (7)
aE. coli rrl numbering was used.
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development of macrolide resistance in M. massiliense lung disease. Therefore, the
consequences of developing macrolide resistance are too important to allow recom-
mendation of macrolide monotherapy for treatment of M. massiliense lung disease
during the continuation phase, even though most patients were effectively treated in
our previous study (18).
In this study, various antibiotics were administered after the diagnosis of macrolide-
resistant M. massiliense lung disease; however, none of the treatment regimens was
successful. Newer agents, such as inhaled amikacin and clofazimine, have shown some
encouraging preliminary results in the treatment of refractory MABC lung disease (26,
27), but optimal antibiotic regimens for M. massiliense lung disease have not been
established. Recently, the U.S. Cystic Fibrosis Foundation and the European Cystic
Fibrosis Society recommended that the continuation phase ofM. abscessus lung disease
treatment include a daily oral macrolide, inhaled amikacin, and two or three additional
oral antibiotics, such as clofazimine, minocycline, or moxiﬂoxacin (4). Further research
is needed to establish optimal treatment regimens for M. massiliense lung disease,
especially macrolide-resistant disease, and to prevent the development of macrolide
resistance during treatment.
In our study, all macrolide-resistant M. massiliense isolates except one had point
mutations at position 2058 or 2059 of the 23S rRNA. Of these point mutations, the most
common was the transition from adenine to guanine at position 2058, consistent with
the ﬁndings of previous studies (20, 22, 28, 29). In previous studies, all clarithromycin-
resistant M. massiliense isolates had rrl mutations (19, 20, 22, 28–30). If macrolide
treatment pressure continues, NTM are likely to develop a stable resistant lineage (31).
However, the acquisition of an rrl mutation obviously confers a bioﬁtness disadvantage
to NTM in the absence of macrolide antibiotics; mutational macrolide resistance thus
appears to occur infrequently in spite of prolonged macrolide monotherapy (18). In the
present study, the one M. massiliense isolate without an rrl mutation had low-level
clarithromycin resistance (MIC, 8 g/ml) (18). Low-level drug resistance can initially be
mediated by activation of an efﬂux pump early in the treatment period. An inactive
efﬂux pump is thought to be the ﬁrst step in acquiring mutational resistance, which is
associated with high-level clarithromycin resistance (32).
Our study had several limitations. First, it was conducted at a single referral center
and included a small number of patients. Second, treatment regimens, including the
addition of intravenous antibiotics, were chosen by the attending physicians, without
an established institutional protocol. Further studies with larger numbers of patients
are needed to evaluate the efﬁcacy of antibiotic therapy in the treatment of macrolide-
resistant M. massiliense lung disease.
In conclusion, we found that macrolide resistance could develop in patients with M.
massiliense lung disease, especially those with large mycobacterial burdens, after
macrolide monotherapy or during weak antibiotic regimens in the continuation phase
after an initiation phase that included multiple intravenous antibiotics. Treatment
outcomes are poor and mortality rates are high after the development of macrolide
resistance. Therefore, preventing the development of macrolide resistance during the
treatment of M. massiliense lung disease is of major concern, and the appearance of
resistance in our patient population underscores the need for more effective therapies
for this disease.
MATERIALS AND METHODS
Study population. We reviewed the medical records for all patients who had macrolide-resistant M.
massiliense lung disease between September 2005 and February 2015, as identiﬁed from the NTM
Registry of Samsung Medical Center (a 1,979-bed referral hospital in Seoul, South Korea). All patients
fulﬁlled the diagnostic criteria for NTM lung disease (3). This retrospective study was approved by the
institutional review board (IRB) of Samsung Medical Center (IRB application no. 2016-07-016). The patient
information was anonymized and deidentiﬁed prior to analysis; therefore, requirements for informed
consent were waived.
Radiographic and microbiological examinations. The ﬁbrocavitary form of the disease (previously
called the upper lobe cavitary form) was deﬁned by the presence of cavitary opacities, mainly in the
upper lobes. The nodular bronchiectatic form was deﬁned by the presence of bronchiectasis and
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multiple nodules on chest HRCT scans, irrespective of the presence of small cavities (diameters of3 cm)
in the lungs (33, 34).
Sputum smears and cultures of AFB were obtained using standard methods (33). During the study
period, NTM species were identiﬁed by a PCR and restriction fragment length polymorphism method
based on the rpoB gene or by reverse blot hybridization assay of the rpoB gene (35–38), followed by
multilocus sequencing analysis of rrs, hsp65, and rpoB (39). DST was performed at the Korean Institute of
Tuberculosis, using the broth microdilution method (40). Isolates with MICs of8 g/ml were considered
clarithromycin resistant (40). MICs for azithromycin were not determined, as clarithromycin is the class
drug for macrolides (40).
M. massiliense isolates were stored at80°C, for further analysis, at the time of detection of macrolide
resistance. The erm(41) gene was detected by PCR sequencing, as described previously (19). For
detection of point mutations at position 2058 or 2059 (Escherichia coli numbering) in the 23S rRNA gene,
we performed PCR to amplify the region corresponding to domain V of the 23S rRNA gene, according
to the method described previously (41). The primers 23SF1 and 23SRIII were used for PCR and
sequencing (41).
Antibiotic therapy and treatment outcomes. Although the initial treatment regimens for macrolide-
susceptible M. massiliense lung disease were standardized (8, 18), treatment regimens for macrolide-
resistant M. massiliense lung disease were not standardized in our institution during the study period.
Patients with mild symptoms when macrolide resistance was detected received oral antibiotics at the
outpatient clinic. Patients with severe symptoms were hospitalized and received intravenous amikacin
(15 mg/kg/day, in two divided doses) and cefoxitin (200 mg/kg/day [maximum of 12 g/day], in three
divided doses) for 2 to 4 weeks. If an adverse reaction associated with cefoxitin occurred, then imipenem
(750 mg, three times per day) was substituted for cefoxitin (8, 18), along with oral antibiotics. For the oral
antibiotics, treatment with a macrolide (clarithromycin at 1,000 mg/day or azithromycin at 250 mg/day)
was continued for all patients and additional drugs, such as a ﬂuoroquinolone (ciproﬂoxacin at 1,000
mg/day or moxiﬂoxacin at 400 mg/day), doxycycline (200 mg/day), linezolid (600 mg/day), trimethoprim-
sulfamethoxazole (320 and 1,600 mg/day), clofazimine (100 mg/day), or inhaled amikacin (250 to 500
mg/day), were used at the discretion of the attending physicians.
Treatment outcomes were assessed by sputum culture conversion after the detection of macrolide-
resistantM. massiliense lung disease; conversion was deﬁned as three consecutive negative cultures, with
the time of conversion deﬁned as the date of the ﬁrst negative culture (8, 18). A favorable outcome was
deﬁned as sputum culture conversion within 12 months after the initiation of treatment and mainte-
nance for 12 months with treatment. Sputum culture conversion was also tested at the end of
treatment.
Statistical analysis. Data are presented as the median and IQR for continuous variables and as
the frequency and percentage for categorical variables. Data were compared with the Mann-Whitney
U test for continuous variables, because of nonnormality, and with Pearson’s chi-square test or
Fisher’s exact test for categorical variables. All tests were two-sided, and P values of 0.05 were
considered signiﬁcant. Data were analyzed using IBM SPSS Statistics for Windows (version 23.0; IBM,
Armonk, NY, USA).
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